Data / Research funding / Pennsylvania / Wistar Institute
Wistar Institute: 101 NIH awards ($209.6M) and 4 NSF awards ($1.9M), fiscal years 2021 to 2026
Wistar Institute in Philadelphia, PA is funded under 101 NIH awards ($209.6M) and 4 NSF awards ($1.9M) in the NIH and NSF award files, read 2026-11-04. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- DW1XZMGNFBL4
- State
- Pennsylvania
Awards
105 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $29,083,069 | August 16, 2021 | April 30, 2027 | MONTANER, LUIS J | reporter.nih.gov |
| Consolidated Basic Cancer Research Program | NIH | National Cancer Institute | 2021 to 2025 | $14,936,465 | April 1, 1997 | February 28, 2026 | ALTIERI, DARIO C | reporter.nih.gov |
| Synthetic DNA-launched and adjuvanted Env immunogens for HIV | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $11,342,707 | December 8, 2022 | November 30, 2027 | WEINER, DAVID B. | reporter.nih.gov |
| SPORE in Skin Cancer | NIH | National Cancer Institute | 2021 to 2025 | $11,313,382 | September 3, 2021 | December 31, 2026 | HERLYN, MEENHARD F | reporter.nih.gov |
| Targeted Therapies in Melanoma | NIH | National Cancer Institute | 2021 to 2023 | $7,414,219 | April 1, 2008 | August 31, 2025 | HERLYN, MEENHARD F | reporter.nih.gov |
| Targeting the Epigenetic and Metabolic Control of EBV-Epithelial Cancers | NIH | National Cancer Institute | 2023 to 2025 | $7,143,256 | May 11, 2023 | April 30, 2028 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| Rational Approaches to Melanoma Therapy | NIH | National Cancer Institute | 2021 to 2025 | $5,361,605 | September 1, 2017 | August 31, 2028 | VILLANUEVA, JESSIE | reporter.nih.gov |
| Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,952,252 | August 1, 2019 | June 30, 2025 | MONTANER, LUIS J | reporter.nih.gov |
| Individualized HIV Curative Combination Strategy against Persistent HIV on ART | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,568,644 | July 7, 2025 | May 31, 2030 | MONTANER, LUIS J | reporter.nih.gov |
| Structural vaccinology guided development of a universal CoV vaccine utilizing nucleic acid delivered nanoparticles | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,517,692 | September 22, 2022 | August 31, 2027 | WEINER, DAVID B. | reporter.nih.gov |
| Tumor Plasticity | NIH | National Cancer Institute | 2021 to 2023 | $3,374,400 | September 1, 2017 | August 31, 2024 | ALTIERI, DARIO C | reporter.nih.gov |
| Drugging EBNA1 to Treat EBV-Associated Cancers | NIH | National Cancer Institute | 2021 to 2025 | $3,259,551 | June 15, 2021 | May 31, 2026 | MESSICK, TROY E | reporter.nih.gov |
| Glycomic Modulation of Gut Microbiome During HIV Infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $3,228,597 | December 24, 2019 | November 30, 2025 | ABDEL MOHSEN, MOHAMED | reporter.nih.gov |
| Role of the p53 P47S mutation in influencing prevalence and immune response to H. pylori | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,013,399 | January 20, 2021 | December 31, 2026 | CLAIBORNE, DANIEL THOMAS | reporter.nih.gov |
| Therapeutic targeting MDSC-mediated immune suppression in cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,755,158 | December 13, 2021 | November 30, 2026 | NEFEDOVA, YULIA | reporter.nih.gov |
| Investigation into the activation of multiple bnAb precursors using structure-designed immunogens and Ig knock-in mice | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,732,799 | November 3, 2022 | October 31, 2027 | ESCOLANO, AMELIA | reporter.nih.gov |
| Manipulating Epitope Immunodominance and Tracking B-cell-Antigen Interactions for Vaccine Design. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,721,210 | September 8, 2022 | August 31, 2027 | ESCOLANO, AMELIA | reporter.nih.gov |
| Training Program in Basic Cancer Research | NIH | National Cancer Institute | 2021 to 2025 | $2,663,448 | July 1, 1976 | July 31, 2027 | GARDINI, ALESSANDRO | reporter.nih.gov |
| Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,613,643 | August 1, 2019 | May 31, 2026 | MONTANER, LUIS J | reporter.nih.gov |
| Host Glycomic Modulation of HIV-associated Neuro-inflammation During Viral Suppression | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $2,534,766 | May 1, 2020 | March 31, 2025 | ABDEL MOHSEN, MOHAMED | reporter.nih.gov |
| Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant Melanoma | NIH | National Cancer Institute | 2022 to 2025 | $2,440,545 | September 1, 2022 | August 31, 2027 | VILLANUEVA, JESSIE | reporter.nih.gov |
| Regulation of EBV Latency by Purine Metabolism and Signaling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,287,875 | May 19, 2021 | April 30, 2027 | TEMPERA, ITALO | reporter.nih.gov |
| A cancer-derived truncating mutation in disease penetrance and progression of MSI CRC | NIH | National Cancer Institute | 2021 to 2024 | $2,262,153 | August 6, 2020 | November 30, 2025 | LIANG, CHENGYU | reporter.nih.gov |
| Functional Analysis of p53 Polymorphic Variants | NIH | National Cancer Institute | 2021 to 2025 | $2,158,835 | June 1, 2005 | November 30, 2026 | MURPHY, MAUREEN E. | reporter.nih.gov |
| Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers | NIH | National Cancer Institute | 2022 to 2025 | $2,147,095 | September 7, 2022 | July 31, 2027 | SALVINO, JOSEPH M | reporter.nih.gov |
| Role of TERRA in Telomere Maintenance and Telomere Stress Response | NIH | National Cancer Institute | 2021 to 2025 | $2,143,051 | July 1, 2010 | January 31, 2026 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| Targeting Siglec-9/Sialoglycan Interactions to Enhance NK Functions During HIV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,127,487 | June 25, 2021 | July 31, 2024 | ABDEL MOHSEN, MOHAMED | reporter.nih.gov |
| Autophagy-mediated defense against inflammation and cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,124,199 | September 21, 2009 | June 30, 2027 | LIANG, CHENGYU | reporter.nih.gov |
| CTCF-dependent mechanisms of ATRX in neuronal differentiation | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,106,664 | July 1, 2022 | June 30, 2027 | SARMA, KAVITHA | reporter.nih.gov |
| New control of oncogene activation in T-cell leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,064,320 | April 12, 2022 | March 31, 2027 | LIANG, CHENGYU | reporter.nih.gov |
| Regulation of Viral Chromatin Architecture During EBV Latency | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,999,128 | April 25, 2018 | May 31, 2029 | TEMPERA, ITALO | reporter.nih.gov |
| Sialic Acid Modulation of HIV-associated Chronic Inflammaging | NIH | National Institute on Aging | 2021 to 2023 | $1,956,508 | May 1, 2019 | August 31, 2024 | ABDEL MOHSEN, MOHAMED | reporter.nih.gov |
| Epigenomic Control of KSHV Latency | NIH | National Cancer Institute | 2021 to 2025 | $1,945,305 | April 1, 2006 | June 30, 2028 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,929,790 | September 1, 2019 | August 31, 2025 | WEINER, DAVID B. | reporter.nih.gov |
| Molecular Mechanism of UV Protection in Cutaneous Melanoma | NIH | National Institute of Environmental Health Sciences | 2021 to 2023 | $1,867,005 | July 29, 2020 | December 31, 2024 | LIANG, CHENGYU | reporter.nih.gov |
| Regulation of neonatal inflammation by myeloid-derived suppressor cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,864,330 | April 15, 2020 | December 31, 2025 | NEFEDOVA, YULIA | reporter.nih.gov |
| EBNA1 Inhibitor for Treatment of EBV-positive DLBCL | NIH | National Cancer Institute | 2023 to 2025 | $1,785,789 | July 7, 2023 | June 30, 2028 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| Multivalent DNA vaccine-mediated protection against Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,773,692 | November 23, 2017 | October 31, 2024 | WEINER, DAVID B. | reporter.nih.gov |
| The impact of coding region variants on mutant p53 biology | NIH | National Cancer Institute | 2021 to 2024 | $1,739,349 | December 1, 2019 | November 30, 2025 | MURPHY, MAUREEN E. | reporter.nih.gov |
| Role of an Integrator-EGR axis in the regulation of myeloid enhancers | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,732,815 | February 1, 2019 | November 30, 2024 | GARDINI, ALESSANDRO | reporter.nih.gov |
| ADNP mechanisms in R-loop regulation during differentiation | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,708,560 | September 6, 2022 | July 31, 2027 | SARMA, KAVITHA | reporter.nih.gov |
| Understanding PPARgamma signaling in melanoma brain metastasis | NIH | National Cancer Institute | 2021 to 2024 | $1,602,434 | December 1, 2019 | October 31, 2024 | CHEN, QING | reporter.nih.gov |
| First-in-human study of two anti-SARS CoV-2 antibodies in health volunteers | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,571,599 | February 23, 2021 | June 30, 2023 | MONTANER, LUIS J | reporter.nih.gov |
| Regulation of alternative cleavage and polyadenylation | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,501,738 | May 1, 2008 | September 30, 2024 | TIAN, BIN | reporter.nih.gov |
| Epigenetic Regulation of Epstein-Barr Virus | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $1,451,108 | January 15, 2022 | December 31, 2026 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| Regulation of gene expression by alternative polyadenylation | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $1,380,334 | April 1, 2024 | March 31, 2029 | TIAN, BIN | reporter.nih.gov |
| The genetics of tumor suppression by p53 | NIH | National Cancer Institute | 2023 to 2025 | $1,278,064 | April 3, 2023 | March 31, 2028 | MURPHY, MAUREEN E. | reporter.nih.gov |
| Transcriptional Reprogramming in Melanoma Plasticity | NIH | National Cancer Institute | 2024 to 2025 | $1,209,297 | July 18, 2024 | June 30, 2026 | LIANG, CHENGYU | reporter.nih.gov |
| Characterizing the sources, mechanisms, and translational relevance of microbial TMAO in driving anti-tumor immunity in pancreatic cancer. | NIH | National Cancer Institute | 2024 to 2025 | $1,154,029 | March 6, 2024 | February 28, 2029 | SHINDE, RAHUL SURESH | reporter.nih.gov |
| Advancing Cancer Research through Comprehensive Proteomics and Metabolomics Analyses | NIH | National Cancer Institute | 2021 to 2025 | $1,137,079 | September 20, 2017 | August 31, 2027 | TANG, HSIN-YAO | reporter.nih.gov |
| Developing potent HIV-specific CAR T cells through optimizing antigen sensitivity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,117,190 | June 7, 2024 | April 30, 2029 | CLAIBORNE, DANIEL THOMAS | reporter.nih.gov |
| Remodeling of the host epigenome during EBV infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,096,596 | June 7, 2024 | April 30, 2029 | TEMPERA, ITALO | reporter.nih.gov |
| Parkin tumor suppression | NIH | National Cancer Institute | 2024 to 2025 | $999,252 | August 5, 2024 | July 31, 2029 | ALTIERI, DARIO C | reporter.nih.gov |
| R-loop functions in neuronal gene expression and genome organization | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $971,065 | March 1, 2024 | February 28, 2029 | SARMA, KAVITHA | reporter.nih.gov |
| Metabolic and molecular regulation of myeloid cell functions in brain cancer | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $959,938 | April 15, 2023 | March 31, 2028 | VEGLIA, FILIPPO | reporter.nih.gov |
| Negative regulation of myeloid-derived suppressive cells in cancer | NIH | National Cancer Institute | 2021 to 2022 | $933,063 | December 18, 2017 | November 30, 2023 | NEFEDOVA, YULIA | reporter.nih.gov |
| Regulation of tumor recurrence by stress activated neutrophils | NIH | National Cancer Institute | 2021 to 2022 | $911,350 | June 1, 2020 | January 31, 2023 | ZHANG, RUGANG | reporter.nih.gov |
| Investigating p16 Loss in Pro-tumorigenic Metabolism | NIH | National Cancer Institute | 2025 | $874,892 | April 1, 2020 | August 31, 2027 | AIRD, KATHERINE MARIE | reporter.nih.gov |
| Computational methods for discovery of disease-modulating microbial genes | NIH | National Library of Medicine | 2024 to 2025 | $838,243 | May 1, 2024 | February 29, 2028 | AUSLANDER, NOAM | reporter.nih.gov |
| Lipids and Myeloid Cell Function in Cancer | NIH | National Cancer Institute | 2021 to 2022 | $796,434 | September 1, 2012 | June 30, 2024 | MONTANER, LUIS J | reporter.nih.gov |
| Regulation of EBV Latency by EBNA1 | NIH | National Cancer Institute | 2021 to 2022 | $754,187 | August 1, 2002 | June 30, 2023 | LIEBERMAN, PAUL M. | reporter.nih.gov |
| Integrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center Level | NIH | National Cancer Institute | 2021 to 2025 | $751,310 | September 15, 2016 | August 31, 2026 | KOSSENKOV, ANDREW V | reporter.nih.gov |
| Stress Response Functions of ADAR1 Regulated by MAP Kinases | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $750,124 | February 1, 2019 | January 31, 2024 | NISHIKURA, KAZUKO | reporter.nih.gov |
| Modeling cancer evolution for prediction with neural networks: methods and applications | NIH | National Cancer Institute | 2021 to 2023 | $747,000 | August 1, 2020 | July 31, 2024 | AUSLANDER, NOAM | reporter.nih.gov |
| Defining the Role of the Cancer Circadian Clock in Tumor Immunity and Tumorigenesis | NIH | National Cancer Institute | 2021 to 2022 | $733,858 | January 1, 1990 | September 30, 2022 | DANG, CHI V. | reporter.nih.gov |
| Integrated analyses of the epigenome to understand the molecular basis of hematopoietic malignancies | NIH | National Cancer Institute | 2023 to 2025 | $730,949 | December 15, 2021 | August 31, 2026 | SRIVASTAVA, AVI | reporter.nih.gov |
| A First-in-Human Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib | NIH | National Cancer Institute | 2021 to 2022 | $726,554 | August 20, 2021 | July 31, 2023 | ALTIERI, DARIO C | reporter.nih.gov |
| Defining metabolic adaptations within the PDAC "arid" tumor microenvironment | NIH | National Cancer Institute | 2021 to 2022 | $702,169 | May 1, 2021 | September 30, 2022 | DANG, CHI V. | reporter.nih.gov |
| MEPCS (Multi-epitope protease cleavage sites) vaccine for protecting against SIV rectal transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $657,563 | July 1, 2025 | June 30, 2029 | LI, QINGSHENG | reporter.nih.gov |
| Tri-State Expansion, Curriculum Evolution, and Equity during BioTechnician Training (Tri ExCEEd BTT) | NSF | Workforce & Talent Continuum Section | 2024 | $649,971 | September 1, 2024 | August 31, 2027 | Kristy S McGuire | nsf.gov |
| Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer | NIH | National Cancer Institute | 2021 to 2022 | $637,231 | July 18, 2019 | January 31, 2023 | ZHANG, RUGANG | reporter.nih.gov |
| Purchase of a SARRP 200 Platform for Irradiation | NIH | Office of the Director, National Institutes of Health | 2022 | $600,000 | August 1, 2022 | July 31, 2023 | MURPHY, MAUREEN E. | reporter.nih.gov |
| Purchase of an Echo 650 acoustic liquid handler with Access workstation | NIH | Office of the Director, National Institutes of Health | 2021 | $566,728 | July 1, 2021 | June 30, 2022 | SALVINO, JOSEPH M | reporter.nih.gov |
| Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer | NIH | National Cancer Institute | 2021 to 2022 | $553,886 | December 1, 2015 | January 31, 2023 | ZHANG, RUGANG | reporter.nih.gov |
| Single-cell Analysis of Glycomic and Proteomic Features of the HIV Reservoir | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $529,605 | August 1, 2022 | July 31, 2025 | ABDEL MOHSEN, MOHAMED | reporter.nih.gov |
| Interrogating Type I Interferon signaling in breast cancer brain metastasis | NIH | National Cancer Institute | 2024 | $529,002 | December 1, 2023 | November 30, 2028 | CHEN, QING | reporter.nih.gov |
| Molecular and neurodevelopmental consequences of ADNP mutation | NIH | National Institute of Mental Health | 2021 to 2022 | $523,663 | September 20, 2021 | December 31, 2023 | SARMA, KAVITHA | reporter.nih.gov |
| Development of Broad Coronavirus Immunity Targeting the Fusion Peptide | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $503,332 | June 9, 2021 | May 31, 2023 | KULP, DANIEL | reporter.nih.gov |
| Developing a genomic toolkit to identify RNAs within non-canonical DNA structures | NIH | National Institute of General Medical Sciences | 2022 to 2023 | $501,325 | September 22, 2022 | August 31, 2025 | SARMA, KAVITHA | reporter.nih.gov |
| Engineering HIV-resistant CAR T cells for a functional HIV cure | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $498,645 | August 19, 2022 | July 31, 2024 | CLAIBORNE, DANIEL THOMAS | reporter.nih.gov |
| Design of vaccination strategies to elicit broadly neutralizing antibodies against HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $498,000 | September 1, 2019 | August 31, 2023 | ESCOLANO, AMELIA | reporter.nih.gov |
| dsRNA production and sensing during DNA virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $498,000 | August 3, 2021 | August 31, 2025 | PRICE, ALEXANDER MATTHEW | reporter.nih.gov |
| Regulation of R-loop Formation and Genome Stability by ADAR1 | NIH | National Institute of General Medical Sciences | 2021 | $479,470 | July 1, 1991 | August 31, 2023 | NISHIKURA, KAZUKO | reporter.nih.gov |
| The role of gut microbe-derived choline metabolites in driving the pro-inflammatory macrophage phenotype and restricting pancreatic cancer | NIH | National Cancer Institute | 2021 to 2022 | $476,604 | July 22, 2021 | June 30, 2023 | SHINDE, RAHUL SURESH | reporter.nih.gov |
| REU Site: Molecular Basis of Cellular Phenotypes (MBCP) | NSF | Infrastructure, Institutes, & Centers | 2026 | $465,318 | November 1, 2026 | October 31, 2029 | David Zuzga | nsf.gov |
| Targeting TERT in Melanoma | NIH | National Cancer Institute | 2021 | $464,587 | March 7, 2017 | February 28, 2024 | VILLANUEVA, JESSIE | reporter.nih.gov |
| Integration of Biomarker Signatures from Peripheral Blood for Diagnosis, Prognosis, Remission and Recurrence of Lung Cancer | NIH | National Cancer Institute | 2021 | $448,182 | April 1, 2016 | March 31, 2022 | SHOWE, LOUISE C. | reporter.nih.gov |
| REU Site: Molecular Basis of Cellular Phenotypes (MBCP) at The Wistar Institute | NSF | Infrastructure, Institutes, & Centers | 2022 | $416,116 | February 1, 2023 | January 31, 2027 | David Zuzga | nsf.gov |
| Scaling Project-Based, Authentic Research and Knowledge in Life Science Innovation | NSF | Education Innovation & Translation Section | 2026 | $399,460 | October 1, 2026 | September 30, 2029 | David Zuzga | nsf.gov |
| Regulation of PRC2 functions by PARP1 | NIH | National Institute of General Medical Sciences | 2021 | $383,271 | August 1, 2017 | July 31, 2023 | TEMPERA, ITALO | reporter.nih.gov |
| Regulation and Functions of 3'UTRs in Cellular Stress | NIH | National Institute of General Medical Sciences | 2021 | $365,020 | September 1, 2018 | August 31, 2023 | TIAN, BIN | reporter.nih.gov |
| Cell intrinsic and extrinsic effects of zinc metabolism in therapy resistant melanoma | NIH | National Cancer Institute | 2025 | $273,065 | April 1, 2025 | March 31, 2030 | AIRD, KATHERINE MARIE | reporter.nih.gov |
| Overcoming the hurdles to successful CAR T cell therapy for a functional HIV cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $270,000 | September 1, 2021 | August 31, 2023 | CLAIBORNE, DANIEL THOMAS | reporter.nih.gov |
| Targeting EZH2 in CARM1-expressing epithelial ovarian cancer | NIH | National Cancer Institute | 2021 | $263,785 | August 18, 2012 | January 31, 2023 | ZHANG, RUGANG | reporter.nih.gov |
| Reprogramming T cell function with multiplexed genome engineering to develop next-generation immunotherapy | NIH | National Cancer Institute | 2025 | $249,000 | March 8, 2024 | May 31, 2028 | ZHOU, XIAOYU | reporter.nih.gov |
| c-Myc Targets in the Pathogenesis of Human Cancers | NIH | National Cancer Institute | 2021 | $225,384 | September 1, 1992 | September 30, 2022 | DANG, CHI V. | reporter.nih.gov |
| Chromatin basis of cellular senescence and its implication in epithelial ovarian cancer | NIH | National Cancer Institute | 2021 | $221,318 | June 1, 2012 | January 31, 2023 | ZHANG, RUGANG | reporter.nih.gov |
| Metabolic and epigenetic reprogramming in cyclin E high ovarian cancer | NIH | National Cancer Institute | 2025 | $212,508 | May 1, 2021 | April 30, 2027 | AIRD, KATHERINE MARIE | reporter.nih.gov |
| Metabolic basis of ARID1A-mutated ovarian cancer | NIH | National Cancer Institute | 2022 | $184,954 | August 1, 2022 | January 31, 2023 | ZHANG, RUGANG | reporter.nih.gov |
| Applying Molecular and Functional Genomics to Identify Biomarkers for Diagnosing and Treating Cancer | NIH | National Cancer Institute | 2021 | $138,169 | September 16, 2019 | October 31, 2021 | GUMIREDDY, KIRANMAI | reporter.nih.gov |
| Genetics of Tumor Suppression by p53 | NIH | National Cancer Institute | 2021 | $119,031 | March 4, 2020 | December 1, 2021 | BARNOUD, THIBAUT | reporter.nih.gov |
| Targeting HSP70 in CARM1-expressing epithelial ovarian cancer | NIH | National Cancer Institute | 2021 | $119,031 | July 1, 2020 | March 31, 2022 | KARAKASHEV, SERGEY | reporter.nih.gov |
| Purchase of MVE Fusion Self-Sustaining Cryogenic Freezers | NIH | Office of the Director, National Institutes of Health | 2022 | $110,540 | June 15, 2022 | June 14, 2023 | MONTANER, LUIS J | reporter.nih.gov |
| Novel Molecular Therapies of Prostate Cancer | NIH | National Cancer Institute | 2021 | $85,800 | July 9, 2010 | July 31, 2022 | ALTIERI, DARIO C | reporter.nih.gov |
| Epigenetic Pathways in ATRX-Mediated CTCF Regulation | NIH | National Institute of General Medical Sciences | 2021 | $66,390 | March 1, 2022 | February 28, 2023 | WULFRIDGE, PHILLIP | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2026 | 0 | $0 | 2 | $864,778 |
| 2025 | 45 | $40,642,726 | 0 | $0 |
| 2024 | 44 | $38,196,710 | 1 | $649,971 |
| 2023 | 47 | $42,297,296 | 1 | $279,098 |
| 2022 | 63 | $44,781,757 | 1 | $137,018 |
| 2021 | 63 | $43,709,213 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 1 award here | |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.396 | November 20, 2026 | Not listed | Same assistance listing 93.396 as 26 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.396 | December 4, 2026 | Not listed | Same assistance listing 93.396 as 26 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.396 | January 7, 2027 | $375,000 | Same assistance listing 93.396 as 26 awards here |
| Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) | PAR-25-221 | NIH | 93.396 | January 7, 2027 | Not listed | Same assistance listing 93.396 as 26 awards here |
| Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) | PAR-27-009 | NIH | 93.396 | January 25, 2027 | Not listed | Same assistance listing 93.396 as 26 awards here |
| Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed) | RFA-CA-28-013 | NIH | 93.396 | February 9, 2027 | $700,000 | Same assistance listing 93.396 as 26 awards here |
| New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional) | PAR-25-272 | NIH | 93.396 | May 7, 2027 | Not listed | Same assistance listing 93.396 as 26 awards here |
| New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional) | PAR-25-279 | NIH | 93.396 | May 7, 2027 | Not listed | Same assistance listing 93.396 as 26 awards here |
| Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | RFA-CA-28-003 | NIH | 93.396 | June 11, 2027 | $600,000 | Same assistance listing 93.396 as 26 awards here |
| Successor-in-Interest (Type 6 Parent Clinical Trial Optional) | PA-24-253 | NIH | 93.396 | July 17, 2027 | Not listed | Same assistance listing 93.396 as 26 awards here |
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) | PA-25-080 | NIH | 93.396 | September 7, 2027 | Not listed | Same assistance listing 93.396 as 26 awards here |
| Investigator-Focused Award (Parent R35) | PAR-28-037 | NIH | 93.396 | October 4, 2027 | Not listed | Same assistance listing 93.396 as 26 awards here |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | RFA-CA-27-019 | NIH | 93.396 | October 19, 2027 | $300,000 | Same assistance listing 93.396 as 26 awards here |
| NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) | PA-25-301 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 26 awards here |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) | PA-25-304 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 26 awards here |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) | PA-25-306 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 26 awards here |
| Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | PAR-24-311 | NIH | 93.396 | January 7, 2028 | $500,000 | Same assistance listing 93.396 as 26 awards here |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) | PAR-25-043 | NIH | 93.396 | January 7, 2028 | $500,000 | Same assistance listing 93.396 as 26 awards here |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed) | PAR-25-044 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 26 awards here |
Topics of its NIH awards
- Genetics
- Cancer
- Biotechnology
- Infectious Diseases
- Immunotherapy
- Rare Diseases
- HIV/AIDS
- Clinical Research
- Human Genome
- Prevention
- Orphan Drug
- Hematology
Updated November 4, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-04). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.